gip/glp-1 agonist Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic glp 1 and gip glp

Nissen expects tirzepatide to soon join the pure GLP-1 RAs with an FDA-approved indication for weight loss in addition to diabetes, although it may meet the same payer reluctance around reimbursement for weight loss that the pure GLP-1 RAs have

Beyond Diabetes and Obesity: Researchers are studying numerous additional indications that could expand the use of these medications beyond diabetes and obesity

GLP-1RAs have demonstrated optimal clinical efficacy when administered as a therapeutic intervention during the early stages of tumor development [36]

The Impact of Tirzepatide on Aortic Inflammation and Atherosclerosis Development To further strengthen the positive impact tirzepatide has on the heart, namely, atherosclerosis reduction [22], a study was conducted on mice involving GIPR and its impact on the cardiovascular system [23]

The SLEEVEPASS trial demonstrated that patients who were randomly assigned to either a laparoscopy sleeve gastrectomy or a laparoscopic Roux-en-Y gastric bypass maintained a 43.5% and 50.7% excess weight loss a decade after the procedure